司美格鲁肽与替尔泊肽在肥胖合并动脉粥样硬化性疾病患者中的心血管结局:一项目标试验模拟研究
本研究利用Komodo Health全国理赔数据,在超重或肥胖合并动脉粥样硬化性心血管疾病(ASCVD)且无糖尿病的成人中,比较司美格鲁肽与替尔泊肽对主要不良心血管事件(MACE)风险的效果。结果显示,修正5点MACE风险在两组间无显著差异(HR=1.21,95%CI:0.99–1.51),次要结局亦无显著差异。敏感性分析点估计方向一致,但强调结果对早期事件、超说明书使用、分析方法和结局定义等决策敏感。
要点
- 在超重/肥胖合并ASCVD且无糖尿病的成人中,司美格鲁肽与替尔泊肽的修正5点MACE风险无显著差异(HR=1.21,95%CI:0.99–1.51)。
- 两组次要结局(修正3点MACE及个体终点)亦无显著差异。
- 敏感性分析显示修正5点MACE点估计方向一致,但结果对早期事件、超说明书使用、分析方法和结局定义敏感。
核心结论
- 在超重或肥胖合并ASCVD且无糖尿病的成人中,司美格鲁肽与替尔泊肽的心血管风险无显著差异。
研究设计与样本
- 采用活性对照、新使用者设计,利用Komodo Health全国理赔数据模拟目标试验。
- 纳入有ASCVD病史且起始治疗前1年内BMI≥27并诊断超重或肥胖、无糖尿病或禁忌证的个体。
- 排除既往使用GLP-1受体激动剂或肥胖药物者。
主要发现
- 修正5点MACE(心肌梗死、卒中、心力衰竭或不稳定型心绞痛住院、冠状动脉血运重建及死亡)风险在司美格鲁肽与替尔泊肽间无显著差异(HR=1.21,95%CI:0.99–1.51)。
- 次要结局(修正3点MACE及个体终点)在两组间亦无显著差异。
- 敏感性分析显示修正5点MACE点估计方向一致,但强调结果对早期事件、超说明书使用、分析方法和结局定义等决策敏感。
局限性
- 敏感性分析显示结果对早期事件、超说明书使用、分析方法和结局定义等决策敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown. The objective was to compare the effectiveness of semaglutide versus tirzepatide on the risk of major adverse cardiovascular events (MACE) in individuals with overweight or obesity and atherosclerotic cardiovascular disease (ASCVD) without diabetes. Materials and Methods This active comparator, new user study emulated a trial using national claims data from Komodo Health. Eligible individuals had a history of ASCVD and, within 1 year prior to initiation: BMI ≥ 27 with a diagnosis of overweight or obesity, continuous insurance coverage and no diabetes or contraindications. Prior GLP-1 receptor agonist or obesity medication users were excluded. The primary outcome was a composite of myocardial infarction, stroke, hospitalization for heart failure or unstable angina, coronary revascularization and mortality (revised 5-point MACE). Secondary outcomes included revised 3-point MACE and individual endpoints. Hazard ratios were estimated using Cox models with inverse probability weighting. Results There was a non-significant difference in risk of revised 5-point MACE (HR = 1.21, 95% CI: 0.99–1.51) or secondary outcomes between semaglutide and tirzepatide. Sensitivity analyses showed directionally consistent point estimates for revised 5-point MACE but highlighted sensitivity to decisions surrounding early events, off-label use, analytic approach and outcome definition. Conclusions Among adults with overweight or obesity and ASCVD without diabetes, there was no significant difference in cardiovascular risk between semaglutide and tirzepatide.
引用
- Diabetes, Obesity and Metabolism:Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。